The primary goal of the study is to determine the local control-rate after radiotherapy (RT) with and without simultaneous integrated boost (SIB) concepts in patients with bone metastases of the spine. Further study objectives are survival, and clinical parameters such as pain, quality of life (QoL) and fatigue. We expect an improvement in local control and consecutively an increased re-sclerotization of the bone metastasis due to a higher biological dose in the tumor area. Therefore patients could benefit in quality-of-life, pain relief and mobility.
The vertebral column is the main localization of bone metastases and is where they frequently indicate an advanced stage of a malignant primary disease \[1, 2\]. Two thirds of all patients with tumors are estimated to develop bone metastases in the course of their disease \[3\]. Spinal bone metastases are of central impact for patients in a palliative setting. The clinical symptoms include pain at rest and under exercise but also impaired activity of daily life, the risk of pathological fractures, and neurological deficits. Local control is the essential factor for stability of the vertebral body of patients with spinal bone metastases. In regard to re-calcification of former osteolytic lesions, palliative radiotherapy (RT) represents an effective treatment option \[4\]. The most common schedule was specified as 30 Gy in 10 fractions. Stereotactic body radiation therapy (SBRT) using intensity-modulated radiotherapy (IMRT) can be a safe modality for treating spinal metastasis with enhanced targeting accuracy \[5\]. Secondly, IMRT to the spine was well tolerated (especially in the spinal cord), had no significant late toxicities, and spared other organs at risk simultaneously \[6\]. The main problem of the standard schedule is the limited dose application to the metastasis due to organ at risk myelon. Therefore, the aims of this study is to apply a high biological dose in the tumor region and to achieve an improved result related to local control for palliative patients with painful spinal bone metastases. Secondly, the aim is to evaluate QoL, fatigue, and survival of three different RT-techniques. To the best of our knowledge, no comparable randomized study has been described in the literature so far.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
Dept of Radiation Oncology, University of Heidelberg, Germany
Heidelberg, Germany, Germany
local control
local control as bone density is assessed 12 weeks post completion of radiotherapy using follow-up CT scan of the spine
Time frame: 3 months after RT
progression-free survival (PFS)
PFS is assessed 2 years post completion of radiotherapy
Time frame: 2 years post completion of radiotherapy
pain reduction
pain is evaluated using the VAS pain scale (0-100 points) at completion and 12/ 24 weeks post completion of radiation
Time frame: end of treatment, 12 and 24 weeks post completion of radiotherapy
Quality of life
Quality of life is assessed using the EORTC BM22 questionnaire at 12 and 24 weeks post completion of treatment
Time frame: 12 and 24 weeks post completion of therapy
Fatigue
Fatigue is assessed using the EORTC FA13 questionnaire
Time frame: 12 and 24 weeks post completion of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
TREATMENT
Masking
NONE
Enrollment
120
Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases